Attention www.globalkeysolutions.net is now www.keypedia.com, read the full press release here.
KeyPedia LogoKeyPedia Icon
  1. Home
  2. /
  3. Records
  4. /
  5. Warning Letter
  6. /
  7. Accentia Biopharmaceuticals, Inc
WARNING LETTER
•Accentia Biopharmaceuticals, Inc

Accentia Biopharmaceuticals, Inc – FDA Warning Letter

Record Details

This FDA Warning Letter, FLA-10-04, dated November 13, 2009, was issued to Accentia Biopharmaceuticals, Inc., following a previous warning letter to (b)(4). The letter identifies several drug products, including (b)(4), (b)(4), (b)(4), and (b)(4), as unapproved new drugs. These products are deemed "new drugs" under Section 201(p) of the Act [21 U.S.C. § 321(p)] because they are not generally recognized as safe and effective for their intended uses.

A key violation is the introduction or delivery of these products into interstate commerce without approved New Drug Applications (NDAs), as required by Sections 301(d) and 505(a) of the Act [21 U.S.C. §§ 331(d) and 355(a)]. Additionally, these prescription drug products are misbranded under Section 502(f)(1) of the Act [21 U.S.C. § 352(f)(1)] because they lack adequate directions for use by a layman, and are not exempt from this requirement. The letter also states these products are adulterated under 21 U.S.C. 351(a)(2)(B).

Accentia Biopharmaceuticals

Company
Accentia Biopharmaceuticals, Inc
Product type
Drugs
Office
Florida District Office
Person
  • Emma R. Singleton (District Director)
View Company Profile

ID · 2e23c12c-e7c1-47e1-9d9e-67d6343ea903

Violation Codes10
21 U.S.C. 321(g)21 U.S.C. 351(a)(2)(B)21 U.S.C. 331(a)21 U.S.C. 321(p)21 U.S.C. 331(d)21.U.S.C. 355(a)21 U.S.C. 355(b)21 U.S.C. 352(f)(1)21 CFR 201.521 CFR 201.115

Full citation text and observation details available on the Dashboard.

Your cart

Your cart is empty.

Browse public document pages and click Buy this document. We'll ask for your email at checkout, no account needed up front.

Browse documents

Discuss this record with AI

KeyPedia

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore Accentia Biopharmaceuticals, Inc
KeyPedia
Regulatory Data Transformed
Stay in the loop

KRA score changes, company updates and news. About monthly, unsubscribe anytime.

Contact
New York Office:
370 Jay Street 7th Floor
Brooklyn, NY 11201
Scranton Office:
Scranton Enterprise Center, Suite 217
201 Lackawanna Avenue
Scranton, PA, 18503
🇺🇸+1 917-789-5099
🇪🇺+48 532-447-507
info@keypedia.com
Quick Links
HomePlatform OverviewMedia
KeyPedia™ Lite
Browse HubDatabase DirectoryRecordsCompaniesOfficesPeopleCareersAbout UsFounding TeamMeet Our ExpertsPartners
Legal & Ethics
Privacy PolicyTerms of ServiceOur Values & MissionCode of Ethics & AI Policy
©2026 KeyPedia™ | Global Key Solutions Corp. All rights reserved.